GSK Abandons Camlipixant Cough Drug: Stock Falls as Much as 4.5%

unlikely to transform patient care

— GSK Plc, statement on July 17, 2026

John Murphy, an analyst at Bloomberg Intelligence, characterizes the Camlipixant failure as a "loss of credibility rather than financial setback" for GSK.

James Gordon, an analyst at Barclays, believes the setback could raise questions about GSK's acquisition strategy, which spent $2 billion to secure Camlipixant.

Michael Leuchten of investment bank Jefferies calls the reversal "manageable" and redirects his focus to GSK's oncology portfolio, whose recent acquisitions he believes offer better value-creation potential.

The £40 Billion Revenue Target by 2031

Luke Miels, GSK's chief executive, is targeting annual revenue of £40 billion (approximately $53.8 billion) by 2031. Some analysts view this goal as challenging to achieve.

Conservative analysts had estimated Camlipixant's annual potential at roughly £430 million by 2031. This figure reflected in part the failure of a similar cough medicine from Merck & Co. to win approval from the FDA (Food and Drug Administration), the U.S. drug regulator, for the same indication.

What Remains Uncertain

GSK has not clarified whether an alternative medicine will replace Camlipixant in its pipeline for refractory chronic cough. The impact of the abandonment on the group's future acquisition strategy has not been disclosed.

7 August 2026 at 11:24

11 August 2026 at 17:54